Chi Yujia, Liu Yiliang, Zhao Jun
Department of Thoracic Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100042, China.
Zhongguo Fei Ai Za Zhi. 2022 Apr 20;25(4):259-265. doi: 10.3779/j.issn.1009-3419.2022.101.17.
Patients with malignant pleural mesothelioma (MPM) usually present with poor prognosis and short survival period, and there has been a lack of effective treatment options for a long time. Chemotherapy has limited improvement in the clinical outcome of advanced patients (the median survival is less than one year), and it is difficult to find suitable targets for targeted therapy. Recent in-depth research on immunotherapy has changed the treatment pattern of MPM. Especially, the dual immunotherapy regimen significantly improved the survival outcome of patients across subgroups and prolonged the survival time of MPM patients. Therefore, it has been approved for unresectable MPM as first-line treatment for patients. The exploration of other mono or combo immunotherapy regimens in the first and second-line settings of MPM is also underway. How to identify the best beneficial population of each regimen through predictive biomarkers is also a hot spot for researchers. This article will focus on the most up-to-date progress of MPM epidemiology, histological characteristics, pathogenesis, treatment patterns and the advances of immunotherapy in the disease. .
恶性胸膜间皮瘤（MPM）患者通常预后较差，生存期短，长期以来缺乏有效的治疗选择。化疗对晚期患者临床结局的改善有限（中位生存期不到一年），且难以找到适合靶向治疗的靶点。近期对免疫疗法的深入研究改变了MPM的治疗模式。特别是，双免疫疗法方案显著改善了各亚组患者的生存结局，延长了MPM患者的生存时间。因此，它已被批准用于不可切除的MPM患者的一线治疗。MPM一线和二线治疗中其他单药或联合免疫疗法方案的探索也在进行中。如何通过预测性生物标志物识别每种方案的最佳受益人群也是研究人员的热点。本文将重点介绍MPM流行病学、组织学特征、发病机制、治疗模式以及该疾病免疫疗法的最新进展。
